MAKNUN, LUK LUIL (2019) STUDI PENGGUNAAN ANTIANEMIA PASIEN GAGAL GINJAL KRONIK YANG MENJALANI HEMODIALISA DI UNIT HEMODIALISA RSUD Dr.ISKAK TULUNGAGUNG PERIODE JANUARI – MARET 2018. Undergraduate thesis, Stikes Karya Putra Bangsa Tulungagung.
![[img]](http://repository.stikes-kartrasa.ac.id/style/images/fileicons/text.png) |
Text
SKRIPSI Luk Luil Maknun.pdf Download (1MB) |
Abstract
Chronic Kidney Failure (CRF) is a disease that occurs after a variety of diseases that damage the period of renal nephron to the point that they are unable to carry out their regulator and external functions to maintain homeostasis. In the human body there is a process called erythropoesis or the formation of red blood cells. This process occurs in the spinal cord, under normal conditions 90% of kidneys produce the hormone erythropoetin which has the function of stimulating the spinal cord to produce red blood cells, so that kidney function decreases the production of the hormone erythropoetin which causes erythrocyte formation to be disrupted, resulting in a decrease in hemoglobin levels or the occurrence of anemia. The aim of the study was to determine the patient profile, the profile of antianemia use and the suitability of antianemia therapy with the clinical practice guide (PPK) of Dr. Iskak Hospital, Tulungagung. The study was conducted using a descriptive method retrospectively by looking at medical record data of patients with CRF who underwent hemodialysis who received antianemia therapy in RSUD dr. Iskak Tulungagung. The sample in this study amounted to 65 patients. From the Data Collection Sheet (LPD) a recapitulation was made then a descriptive analysis of the study of the use of antianemia in patients with CRF who underwent hemodialysis in RSUD dr. Iskak Tulungagung. The results of the study of patients with chronic hemodialysis who received antianemia therapy for the period of January - March 2018 were men (55.4%) aged 47 - 57 years (33.8%) with hemoglobin levels 6.0 - 7.9 g / dl (69, 2%) and the largest comorbidities are anemia (29.2%). Most monotherapy therapy was transfusion of PRC (44.6%), 2 combinations of transfusion PRC + folic acid (32.3%) and 3 combinations of transfusion PRC + folic acid + added blood (7.7%). Of the 65 patients with hemodialysis chronic renal failure, antianemia therapy with PPK RSUD dr. Iskak had a percentage of (78.2%). Keywords: Antianemia, Chronic Kidney Failure, Hemodialysis, RSUD dr. Iskak.
| Item Type: | Thesis (Undergraduate) |
|---|---|
| Uncontrolled Keywords: | Antianemia, Chronic Kidney Failure, Hemodialysis, RSUD dr. Iskak. |
| Subjects: | R Medicine > R Medicine (General) R Medicine > RM Therapeutics. Pharmacology |
| Divisions: | Program Studi > S1 Farmasi |
| Depositing User: | Surya Hadi Prasetyo |
| Date Deposited: | 09 Mar 2022 03:01 |
| Last Modified: | 09 Mar 2022 03:01 |
| URI: | http://repository.stikes-kartrasa.ac.id/id/eprint/49 |
Actions (login required)
 |
View Item |